| Ulcerative Colitis |
1 |
1 |
| Biologic Therapy |
0 |
0.87 |
| Inflammatory Bowel Disease |
0 |
0.66 |
| Colitis |
0 |
0.65 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.48 |
| Medical Life |
0 |
0.44 |
| Match |
0 |
0.4 |
| Anti-Tumor Necrosis Factor (Anti-TNF) |
0 |
0.3 |
| Child |
0 |
0.16 |
| Clinical Research |
0 |
0.16 |
| Food and Drug Administration (FDA) |
0 |
0.99 |
| Arizona |
0 |
0.08 |
| Biomarker |
0 |
0.08 |
| Clinician Health and Well-Being |
0 |
0.08 |
| Interleukin |
0 |
0.08 |
| Intravenous |
0 |
0.08 |
| New York |
0 |
0.08 |
| Outpatient Clinic |
0 |
0.08 |
| Receptors |
0 |
0.08 |
| Tumor |
0 |
0.08 |
| Health Care Reform |
0 |
0.07 |